References
The End of Alzheimer’s Program – Dale E. Bredesen, M.D. References
Following is a list of references from the book, The End of Alzheimer’s Program, published by Avery/Random House. Due to the length of the text, these references could not be included in the print version, and therefore are listed below.
13 – James V. Pottala et al., Neurology 82, no. 5, 435–42, January 2014
Higher RBC EPA + DHA Corresponds with Larger Total Brain and Hippocampal Volumes: WHIMS-MRI Study
13 – Z. S. Tan et al., Neurology 78, no. 9, 658–64, February 2012
Red Blood Cell ω-3 Fatty Acid Levels and Markers of Accelerated Brain Aging
14 – Fredrik Jernerén et al., Journal of Alzheimer’s Disease 69, supplement, 1–9, April 2019
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer’s Disease: The OmegAD Study
15 – Jan Krzysztof Blusztajn, Barbara E. Slack, and Tiffany J. Mellott, Nutrients 9, no. 8, E815, July 2017
Neuroprotective Actions of Dietary Choline
16 – Ramon Velazquez et al., Molecular Psychiatry, November 2018
Maternal Choline Supplementation Ameliorates Alzheimer’s Disease Pathology by Reducing Brain Homocysteine Levels Across Multiple Generations
17 – David Trilling, Journalist’s Research, October 3, 2017
Farmed Versus Wild Salmon: Research Review
18 – Cheryl Long and Tabitha Alterman, Mother Earth News Magazine, November 13, 2011
Meet Real Free-Range Eggs
19 – James A. P. Tomlinson and David C. Wheeler, Kidney International 92, no. 4, 809–15, August 2017
The Role of Trimethylamine N-Oxide as a Mediator of Cardiovascular Complications in Chronic Kidney Disease
19 – James J. Di Nicolantonio, Mark McCarty, and James O’Keefe, Open Heart 6, no. 1, e000890, February 2019
Association of Moderately Elevated Trimethylamine N-Oxide with Cardiovascular Risk: Is TMAO Serving as a Marker for Hepatic Insulin Resistance
20 – Sam F. Peisch et al., World Journal of Urology 35, no. 6, 867–74, June 2017